Noble Capital analyst Robert LeBoyer initiated coverage of Nutriband (NTRB) with an Outperform rating and $13 price target The firm believes the Phase 1 clinical trial will show sufficient abuse deterrence to allow for Nutriband to file a new drug application for approval in the second half of 2025. It anticipates approval in the second half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRB:
- Nutriband CEO still sees Aversa Fentanyl regulatory approval within 2025
- Nutriband Expands AVERSA™ Patent to Macao
- Nutriband extends Chinese patent to Macao for AVERSA technology
- Nutriband reports record revenue for Q3, progress to NDA for AVERSA
- Nutriband receives Hong Kong patent notice of publication for Aversa